Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway

Low-dose naltrexone plays antineoplastic role in cervical cancer progression through suppressing PI3K/AKT/mTOR pathway

The incidence of cervical cancer is increasing annually worldwide. Low-dose naltrexone (LDN) has been reported to delay tumor progression, but the mechanism remains unclear. Here, we found that low-dose naltrexone could upregulate the expression of OGFr. Additionally, LDN could suppress the abilitie...

Full description

Bibliographic Details
Main Authors: Ning Liu, Limei Yan, Fengping Shan, Xiaonai Wang, Na Qu, Mike K Handley, Mingxing Ma
Format: Article
Language:English
Published: Elsevier 2021-04-01
Series:Translational Oncology
Subjects:
Low-dose naltrexone
Cervical cancer
Proliferation
Invasion
PI3K/AKT/mTOR
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523321000206

Internet

http://www.sciencedirect.com/science/article/pii/S1936523321000206

Similar Items